SPC
ATRA icon

Slate Path Capital’s Atara Biotherapeutics ATRA Stock Holding History

Slate Path Capital’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-16,800
Closed -$6.12M – 27
2020
Q2 		$6.12M Hold
16,800
– – 0.36% 22
2020
Q1 		$3.57M Buy
+16,800
New +$5.33M 0.27% 22
2017
Q1 		– Sell
-19,000
Closed -$6.75M – 15
2016
Q4 		$6.75M Hold
19,000
– – 0.21% 15
2016
Q3 		$10.2M Buy
19,000
+2,200
+13% +$1.19M 0.17% 12
2016
Q2 		$9.45M Buy
+16,800
New +$8.06M 0.74% 13

Other funds holding ATRA

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Slate Path Capital's ATRA Position: Q3 2020 in Review

Slate Path Capital sold out of Atara Biotherapeutics (ATRA) in Q3 2020, closing a stake of 16,800 shares — an estimated $6.12M sold.

Slate Path Capital first reported a position in ATRA in Q2 2016 and held it in 5 quarters. The position peaked at $10.2M in Q3 2016. 140 funds tracked by Wall St. Rank hold ATRA as of Q3 2020.

  • Slate Path Capital reported no remaining Atara Biotherapeutics position as of Q3 2020 after selling out during the quarter.
  • Slate Path Capital sold 16,800 Atara Biotherapeutics shares in Q3 2020, an estimated $6.12M.
  • Slate Path Capital first reported a position in Atara Biotherapeutics in Q2 2016 and held it in 5 quarters.
  • Slate Path Capital's Atara Biotherapeutics position peaked at $10.2M in Q3 2016.
  • 140 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q3 2020.

Based on Slate Path Capital's 13F filing for Q3 2020, filed 16 Nov 2020.